Background: Prostate cancer is one of the most prevalent cancers in the male population. To determine the aggressiveness of suspected lesions precisely, predictive models are increasingly being developed using quantitative MRI measurements, and particularly the ADC value. This study aimed to determine whether ADC values could be used to establish the aggressiveness of prostate cancer. Methods: A retrospective single-center study included 398 patients with prostate cancer who underwent a multiparametric MRI prior to radical prostatectomy. DWI ADC values were measured (µm²/s) using b values of 50 and 1000. The dominant lesion best visualized on MRI was analyzed. The ADC values of the index lesion and reference tissue were compared to tumor aggressivity according to the Gleason grade groups based on radical prostatectomy results. Statistical analysis was performed using the Mann–Whitney U test, Kruskal–Wallis H test, Spearman’s rank correlation, and ROC curves. Results: A very strong negative correlation (rs = −0.846, p < 0.001) between ADC and GS was found. ROC analysis revealed an AUC of 0.958 and an ADC threshold value of 758 µm²/s in clinically significant prostate cancer diagnoses using the absolute ADC value, with no advantage of using the ADC ratio over the absolute ADC value being identified. Conclusion: DWI ADC values and the calculated ADC ratio have a significant inverse correlation with GS. The findings indicate a strong capability in determining prostate cancer aggressiveness, as well as the possibility of assisting with assigning PI-RADS categories using ADC as quantitative metrics.

Background and Objectives: Acute ischemic stroke (AIS) caused by large vessel occlusion (LVO) remains a major cause of disability and mortality. Mechanical thrombectomy (MT) improves outcomes, but recovery varies. This study assessed the prognostic value of hypoperfusion intensity ratio (HIR), collateral circulation, and other clinical/imaging factors. Materials and Methods: This retrospective cohort study included 96 LVO patients treated with MT with or without intravenous thrombolysis (IVT) between 2020 and 2024 at a tertiary hospital. Inclusion required multimodal CT (CT, CTA, CTP) and clinical data (NIHSS, mRS). HIR, core volume, CBV index, mismatch ratio, and collateral status were evaluated using artificial intelligence (AI)-based software. Univariate/multivariate logistic regression identified predictors of poor outcome (mRS > 3 at 90 days). Results: Lower HIR (<0.5) and good collaterals were associated with favourable outcomes (p < 0.001). Multivariate analysis identified HIR, initial NIHSS, and procedure duration as independent predictors of poor outcome. CTP-derived core volume, cerebral blood volume index, and mismatch ratio were also significant predictors. ROC analysis showed the highest AUC for core volume (0.810). Diabetes mellitus was associated with a worse prognosis compared to other clinical factors. Conclusions: HIR and collateral status are independent predictors of functional recovery after MT. CTP-derived core volume and CBV index have strong prognostic value. AI-based perfusion analysis supports patient selection and risk stratification.

Background: Liver damage in COVID-19 is multifaceted, including liver steatosis and inflammation. Multiparametric ultrasound (mpUS) is an imaging modality that has the capacity to evaluate various facets of overall liver health and is relatively accessible and thus is an excellent choice to determine parenchymal changes. Methods: A longitudinal prospective study was designed to evaluate long-term hepatic damage following COVID-19 using mpUS. Patients were assessed within a 3–6-month period after the initial episode of COVID-19 and subsequently had a follow-up after 3 years compared to a control group. Liver stiffness (2D-SWE), attenuation (ATI), and shear wave dispersion (SWD) were measured to quantify liver stiffness, steatosis, and tissue viscosity. Results: A total of 129 patients were scanned at the baseline assessment, 90 patients in research group (58 patients had a follow-up) and 39 as a clinically healthy control group, and all were included in the follow-up for evaluation after 3 years. The mpUS evaluation in research group revealed a median SWE decrease from 5.04 ± 1.74 kPa to 4.59 ± 0.81 kPa and SWD decrease from 11.88 ± 1.73 m/s/kHz to 10.83 ± 1.49 m/s/kHz (p > 0.05); in contrast, median ATI values showed slight increase over time—0.56 ± 0.09 dB/cm/MHz to 0.60 ± 0.09 dB/cm/MHz (p > 0.05). Control group was stratified according to subsequent COVID-19 status. In both the COVID-negative and -positive subgroups SWE slightly increased from initial 4.55 ± 0.78 kPa to 4.8 ± 0.88 kPa and 4.7 ± 1.29 kPa, median SWD had a slight decrease from initial 10.80 ± 1.73 m/s/kHz to 10.15 ± 1.87 m/s/kHz and 10.6 ± 1.82 m/s/kHz (p > 0.05), and ATI increased significantly from initial 0.57 ± 0.08 dB/cm/MHz to 0.62 ± 0.09 dB/cm/MHz and 0.65 ± 0.07 dB/cm/MHz (p < 0.05), respectively. Conclusions: The study found that initially COVID-19-affected patients showed stable ATI and BMI values, no hepatic steatosis, normal SWE, and reduced dispersion which suggests resolving inflammation without fibrosis. Controls showed increased ATI and mild steatosis, likely linked to BMI and metabolic changes rather than direct viral liver injury.